Becton Dickinson Pty Ltd v B. Braun Melsungen AG

Link copied
Case Copied 76 min read

FEDERAL COURT OF AUSTRALIA

Becton Dickinson Pty Ltd v B. Braun Melsungen AG [2018] FCA 1692

File number: NSD 1297 of 2014
Judge: NICHOLAS J
Date of judgment: 9 November 2018
Catchwords:

PATENTS – claims for catheter insertion device – claim construction – meaning of “needle protective device” – whether claims infringed

PATENTS – whether claims entitled to priority date based on prior application – whether claims fairly based on matter disclosed in prior application

PATENTS – whether claims invalid for non-compliance with s 40(3) on the ground that they are not fairly based on the matter described in the specification

PATENTS – inventive step – whether claims invalid for lack of inventive step  

Legislation:

Patents Act 1990 (Cth) s 18(1)(b)(ii), 40(3), 79B(1), 128

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Patent Regulations 1991 (Cth) reg 3.12  

Cases cited:

Aktiebolaget Hassle v Alphapharm Pty Ltd (2002) 212 CLR 411

Allsop Inc v Bintang Ltd (1989) 15 IPR 686

AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324

AstraZeneca AB v Apotex Pty Ltd (2015) 257 CLR 356

Commonwealth Industrial Gases Ltd v MWA Holdings Pty Ltd (1970) 180 CLR 160

Decor Corp Pty Ltd v Dart Industries Inc (1988) 13 IPR 285

ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (1999) 45 IPR 577

Jupiters Ltd v Neurizon Pty Ltd (2005) 222 ALR 155

Kimberly-Clark Australia Pty Limited v Multigate Medical Products Pty Limited (2011) 92 IPR 21

Kirin-Amgen Inc v Hoechst Marion Roussel Ltd (2004) 64 IPR 444

Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274

Martin v Scribal Pty Ltd (1954) 92 CLR 17

Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Ltd (1980) 144 CLR 253

Multigate Medical Devices Pty Ltd v B Braun Melsungen AG (2016) 117 IPR 1

Olin Mathieson Chemical Corp v Biorex Laboratories Ltd [1970] RPC 157

Pharmacia Italia SPA v Mayne Pharma Pty Ltd (2005) 222 ALR 552

Rehm Pty Ltd v Webster Security System (International) Pty Ltd (1988) 81 ALR 79

Sachtler GmbH & Co KG v RE Miller Pty Ltd (2005) 65 IPR 605

Tramanco Pty Ltd v BPW Transpec Pty Ltd (2014) 105 IPR 18

Vickers, Sons & Co Ltd v Siddell (1890) LR 15 App Cas 496

Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262

Welsh Perrin & Co Pty Ltd v Worrell (1961) 106 CLR 588

Date of hearing: 5, 6, 7, 8, 9, 14, 15 and 16 June 2017
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 346
Counsel for Becton Dickinson Pty Ltd: Mr CA Moore SC with Mr AR Lang
Solicitor for Becton Dickinson Pty Ltd: Herbert Smith Freehills
Counsel for B. Braun Melsungen AG: Mr D Shavin QC with Mr EJC Heerey QC
Solicitor for B. Braun Melsungen AG: Davies Collison Cave
Table of Corrections
5 December 2018 Para [259] first sentence “indication”…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Becton Dickinson Pty Ltd v B. Braun Melsungen AG and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCA 1692
Decision Date

CaseChat Overview and Summary

The case of Becton Dickinson Pty Ltd v B. Braun Melsungen AG involved a dispute over patent claims related to a catheter insertion device, with the central issue being whether certain claims were valid and infringed. The matter was heard in the Federal Court of Australia. The court was tasked with determining several legal issues, including the construction of the term "needle protective device" in the patent claims, whether the claims were entitled to a priority date from a prior application, if the claims were fairly based on the matter disclosed in the specification, and if the claims were valid and had not been rendered obvious by prior art.

In addressing these issues, the court examined the meaning of "needle protective device" and found that it did not include a blood control mechanism. The court also held that the claims were entitled to the priority date from the prior application and were fairly based on the matter disclosed in the specification. The court rejected the argument that the claims were invalid for lack of inventive step, as it found that the Fresenius blood control mechanism was not part of the common general knowledge in Australia as of the priority date. As a result, the court dismissed the originating application, the amended notice of cross-claim, and the amended notice of further cross-claim, and revoked certain claims in the patents in question.

The court ordered that the respondent prosecute any appeal expeditiously and serve copies of the orders on the Commissioner of Patents. The revocation of certain claims was stayed pending any appeal or its final determination. The parties were also directed to exchange brief written submissions on questions of costs. This decision clarified the scope of the patent claims and affirmed the validity of certain aspects of the patents in dispute.

Orders

Orders of the court

1. The originating application be dismissed.

2. The amended notice of cross-claim be dismissed.

3. Claims numbered 14 and 26 in Australian Patent No 2012244163 be revoked.

4. Claim numbered 17 in Australian Patent No 2012244164 be revoked.

5. Claim numbered 10 in Australian Patent No 2013201814 be revoked.

6. The amended notice of further cross-claim be otherwise dismissed.

7. Within 14 days, the parties file and serve (by way of exchange) brief written submissions (limited to 3 pages in length) on questions of costs.

8. Within 21 days, the parties file and serve (by way of exchange) brief written submissions in reply (limited to 2 pages in length) on questions of costs.

9. Upon the respondent, by its counsel, undertaking to the Court during the period of the stay:

A. to prosecute any appeal expeditiously; and

B. forthwith to serve on the Commissioner of Patents copies of these orders pursuant to s 140 of the Patents Act 1990 (Cth) with a request that particulars of Orders 3, 4 and 5 (“the Revocation Orders”) be registered in accordance with section 187 of the Patents Act 1990 (Cth),

the Revocation Orders be stayed:

(a) initially for a period of 21 days from today; and

(b) if an appeal from any of the Revocation Orders is lodged within that period, until the final determination of that appeal or further order.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

In my view the evidence does not establish that the Fresenius blood control mechanism formed part of the common general knowledge in Australia as at the priority date. It follows that Becton’s challenge to the validity of the relevant claims for lack of inventive step fails. Criticism of Mr Crawford’s evidence Braun submitted that Mr Crawford’s evidence in relation to his hypothetical design task should be given little weight. It submitted that he had prior knowledge of the invention described in the Patents, and that his description of the hypothetical design task that he says he would have performed was the product of a large measure of hindsight. Mr Crawford worked on a special project at Becton in the late 1980s or early 1990s to develop what he referred to as the “Combined Device” which was an IV catheter device providing needle protection and a valve for blood outflow control. In the course of working on various features which were included in Becton’s prototype product, Mr Crawford and his colleagues at Becton developed at least three patented inventions. They also developed functional prototypes of the Combined Device. Although the product was the subject of a clinical trial, it was not published or released for sale. Mr Crawford said that the decision by Becton’s management not to commercialise the product was, for him, disappointing but understandable. He said that there were issues with the way the product worked. Mr Crawford worked with the inventor, Mr Woehr, for several years prior to 1989 in Becton’s research and development department before Mr Woehr left Becton to work for Braun. I think it is likely that Mr Crawford showed continuing interest in Mr Woehr’s research and development work while Mr Woehr was working for Braun. While working for Becton, Mr Crawford made a practice of reviewing patent applications for the purpose of monitoring the research and development activities of Becton’s competitors. These patent applications included Braun’s application for the US equivalent of the Parent which was published on 13 July 2006 at a time when Mr Crawford was still working for Becton and after Mr Woehr had left Becton to work for Braun. In his oral evidence Mr Crawford agreed that it was more likely than not that he reviewed the US application. I am satisfied that he read the US application soon after it was published. I am also satisfied that he would have studied it very closely. Mr Crawford said it was “a remarkable coincidence” that his design was so close to Mr Woehr’s design. When asked if this coincidence might be explained on the basis that the two designs were an obvious way to do something, Mr Crawford said:… it’s just engineering. There are just obvious solutions to a problem of co-locating a valve actuating element inside of a catheter adapter with a tip shield … I don’t know how else you would do it. It seems obvious to me that that is the engineering solution. Mr Crawford gave similar evidence in re-examination as to why he and Mr Woehr arrived at what was essentially the same design. He said, in effect, that the prior art provided good solutions for the design problem involving straightforward modifications to known elements.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.